Total raised
$63.8M
Last: PIPE 2026-01
Stage
Public
Founded
2004
Headcount
4
HQ
Giv'atayim
Sector
Health Tech & Life Sciences
About
SciSparc is a specialty clinical-stage pharmaceutical company focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company is currently engaged in drug development programs based on THC and/or non-psychoactive cannabidiol (CBD), including SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimers disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.
Funding history · 6 rounds · $63.8M total
2026-01
PIPE
$9.2M
2023-10
PIPE
$5.0M
2022-06
PIPE
$10.0M
2021-03
PIPE
$8.2M
2019-12
PIPE
$1.3M
2019-04
PIPE
$2.3M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did SciSparc (formerly Therapix Biosciences) first list on NASDAQ?
- SciSparc, under its former name Therapix Biosciences, first listed on NASDAQ in March 2017.
- What was the total amount raised by SciSparc through funding rounds?
- According to startupim data, SciSparc has raised a total of $63,756,000 through various funding rounds. For a full financing history, please refer to startupim.
- What is SciSparc's primary focus in drug development?
- SciSparc is a clinical-stage pharmaceutical company focused on developing technologies and assets based on cannabinoid pharmaceuticals, including THC and non-psychoactive cannabidiol (CBD).
- Which medical conditions are SciSparc's drug development programs targeting?
- SciSparc is engaged in drug development programs targeting Tourette syndrome, obstructive sleep apnea, Alzheimer's disease and agitation (with SCI-110), pain (with SCI-160), and autism spectrum disorder and epilepsy (with SCI-210).
- When did SciSparc announce the successful completion of its acquisition of an IP portfolio for the endoscope market?
- In January 2026, SciSparc announced the successful completion of the acquisition of an IP portfolio for the endoscope market, advancing towards immediate commercialization.
- What was the outcome of SciSparc's lawsuit settlement in February 2025?
- In February 2025, SciSparc secured a favorable settlement in a lawsuit it filed, receiving cash compensation and a full release from all commitments, royalties, and allegations related to claimed core technology.
- What was a significant development for SciSparc's Tourette Syndrome treatment in September 2024?
- In September 2024, SciSparc received FDA approval to initiate its Phase IIb clinical trial for Tourette Syndrome treatment in the US.
- What was the status of SciSparc's clinical trial for children with Autism Spectrum Disorder in December 2024?
- In December 2024, SciSparc announced the renewal of approval by the Israeli Medical Cannabis Agency for its clinical trial in children with Autism Spectrum Disorder.
- What was the outcome of the proposed merger between SciSparc and AutoMax in October 2025?
- In October 2025, SciSparc and AutoMax called off their merger, despite shareholders having approved it in August 2025.
- What was the latest PIPE funding round for SciSparc?
- SciSparc's latest PIPE funding round occurred in January 2026, raising $9,180,000.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical Cannabis
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
chronic-painpain-reliefcns-disordersdrug-developmentapneapharmaceuticalsautismchronic-diseasealzheimers-diseaseinfectious-diseasemental-healthcancermedical-cannabisimmunotherapyepilepsytherapeuticsdrug-delivery